Juan Fco. Lisón
Valencia, Valencia-valència, 46006, Spain
Location status: Recruiting
NCT Number: NCT06948500
The primary aim of this randomized controlled trial is to determine the efficacy of a 6-week immersive virtual reality (IVR)-based therapeutic exercise intervention, which manipulates visual proprioceptive input during exercise, for patients diagnosed with fibromyalgia (FM). Participants will be randomly allocated into two groups: an experimental group performing therapeutic exercises integrated with IVR featuring modified visual feedback, and a control group executing identical exercises without IVR integration. The primary outcome will assess the impact of fibromyalgia on daily activities, while secondary outcomes will comprehensively evaluate fatigue, sleep quality, severity of fibromyalgia symptoms, health-related quality of life, anxiety and depressive symptoms, fear-avoidance beliefs, pain catastrophizing, kinesiophobia, indicators of central sensitization, lumbar spine flexion and extension range of motion, somatosensory function, body perception distortion, muscle strength of the handgrip and quadriceps, functional mobility, lower limb strength, behavioral regulation concerning exercise adherence, and patient-reported experiences regarding IVR use. This trial seeks to elucidate whether incorporating IVR into therapeutic exercise protocols reduces the impact of fibromyalgia on patients' daily lives and improves physiological, psychological, and physical outcomes compared to traditional exercise approaches without IVR.
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Not applicable
Valencia, Valencia-valència, 46006, Spain
Location status: Recruiting
Fibromyalgia is a chronic and multifactorial condition marked by widespread pain, fatigue, sleep disturbances, and various neurocognitive and psychosomatic symptoms, severely impacting quality of life and increasing healthcare costs. Although therapeutic exercise is a first-line, evidence-based treatment, its implementation is often hindered by low adherence, kinesiophobia, and maladaptive pain beliefs. Immersive virtual reality (IVR) has gained attention as a novel approach to enhance exercise efficacy through sensory immersion, cognitive distraction, and embodiment. Visual feedback manipulation in IVR-such as creating the illusion of reduced movement-has been shown to increase range of motion and engagement without intensifying perceived pain or effort. While non-immersive VR systems have shown benefits in symptom management and adherence, IVR appears to offer superior outcomes via real-time multisensory integration. However, no studies have yet investigated the clinical effects of integrating IVR with altered visual input during therapeutic exercise in FM. This will be a randomized controlled trial evaluating a 6-week IVR-based exercise program that modulates visual input to create the perception of reduced movement in FM patients. The experimental group will be compared to a control group following the same exercise program without IVR. Outcome measures include pain intensity, fatigue, sleep quality, kinesiophobia, functional capacity, symptom severity, and user experience. This study seeks to fill a critical gap in FM rehabilitation by testing whether IVR-enhanced exercise with visual modulation reduces the impact of fibromyalgia on patients' daily lives and improves physiological, psychological, and physical outcomes compared to traditional exercise approaches without IVR.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will wear an HTC Vive Pro head-mounted display with waist, hand and foot trackers during 60-min sessions, 2 times/week for 6 weeks (12 sessions). A gender- and skin-tone-matched first-person avatar will be calibrated to the user's anthropometrics and will mirror all real-time movements. Standardised audio instructions will be played through the headset; a virtual mirror will provide visual feedback.
To facilitate lumbar mobility, two sensorimotor illusions will be applied: (1) Flexion illusion: Avatar upper-limb length will be reduced by ≈20%, encouraging greater trunk flexion; (2) Extension illusion: A virtual bar will rise with lumbar extension but will under-represent real movement by ≈10%. Both manipulations will update continuously throughout each repetition. A physiotherapist will supervise every session and will record adverse events.
Participants will undertake a 6-week therapeutic exercise program, consisting of two sessions per week (12 sessions total), with a primary objective of reducing fibromyalgia's impact on daily life. Each session will involve ten exercises performed in one or two sets each, depending on the week of the protocol. Exercise repetitions and intensity will be individualized using the Borg Rating of Perceived Exertion (RPE) scale (6-20), maintaining an intensity range of RPE 13-17. Specifically, intensity will start at RPE 14 (moderate) in Weeks 1-2, increase to RPE 15 (moderate-high) in Weeks 3-4, and peak at RPE 16 (high) in Weeks 5-6. No external load will be applied during the first three weeks to allow participants to adapt to the program, while progressive resistance will be introduced during the final three weeks according to individual capacity, ensuring a safe and gradual overload.
Time frame: At six weeks
Measured with Spanish version of the Revised Fibromyalgia Impact Questionnaire (FIQR). This 21-item instrument evaluates physical function (0-30), overall impact (0-20), and symptom severity (0-50), yielding a total score from 0 to 100, with higher scores indicating greater impairment.
Time frame: At six weeks
Fatigue will be assessed using the Spanish version of the Multidimensional Fatigue Inventory (MFI-20), a validated 20-item self-report instrument measuring five dimensions: general and physical fatigue, reduced activity and motivation, and mental fatigue. Items are scored on a 5-point Likert scale, yielding total scores from 20 to 100, with higher scores indicating greater fatigue.
Time frame: At six weeks
Measured using the validated Spanish version of the Pittsburgh Sleep Quality Index (PSQI), a 19-item self-report measure evaluating sleep over the past month across seven components. Total scores range from 0 to 21, with higher scores indicating poorer sleep.
Time frame: At six weeks
Assessed with the Widespread Pain Index (WPI; 0 - 19), the 19 item body map component of the 2016 ACR Fibromyalgia criteria. Participants mark each anatomical region in which they have experienced pain during the previous week; the total score corresponds to the number of painful sites, ranging from 0 (no pain) to 19 (pain in all sites), with higher scores indicating a wider pain distribution and greater disease burden.
Time frame: At six weeks
Measured with the Symptom Severity Scale (SSS; 0 - 12), the second component of the 2016 ACR Fibromyalgia criteria. Participants rate the severity of fatigue, non-restorative sleep, cognitive problems and extent of additional somatic symptoms on 0 to 3 Likert items (0 = none, 3 = severe). Scores are summed to yield a total ranging from 0 (no symptoms) to 12 (maximal severity), with higher values reflecting a greater symptom severity.
Time frame: At six weeks
The FSDC total score will be calculated by summing the Widespread Pain Index (WPI) and Symptom Severity Scale (SSS) scores. This yields an aggregate score ranging from 0 to 31, with higher values reflecting a greater overall fibromyalgia symptom burden.
Time frame: At six weeks
Measured using the Spanish EQ-5D-5L, a validated self-reported tool measuring five dimensions on five severity levels. Responses yield an index score (-0.5 to 1.0), with lower values indicating worse health, calculated using the Spanish value set.
Time frame: At six weeks
Assessed using the Spanish version of the Hospital Anxiety and Depression Scale (HADS), a 14-item self-report tool comprising two subscales, HADS-Anxiety and HADS-Depression, each scored 0-21. Items are rated on a 4-point Likert scale (0-3), with higher scores indicating greater severity.
Time frame: At six weeks
Measured using the Spanish version of the 13-item Pain Catastrophizing Scale (PCS), which evaluates the frequency of catastrophic thoughts and feelings related to pain across three subscales: rumination, magnification, and helplessness. Items are rated from 0 to 4, yielding a total score of 0-52, where higher scores indicate greater catastrophizing.
Time frame: At six weeks
Assessed using the Spanish version of the 16-item Fear-Avoidance Beliefs Questionnaire (FABQ), scored on a 7-point Likert scale (0-6), where higher scores indicate stronger avoidance beliefs.
Time frame: At six weeks
Assessed using the Spanish version of the Tampa Scale for Kinesiophobia (TSK-11), an 11-item self-report measure of fear of movement and reinjury. Items are scored on a 4-point Likert scale (1-4), with total scores ranging from 11 to 44. Higher scores indicate greater kinesiophobia.
Time frame: At six weeks
Measured using the Central Sensitization Inventory (CSI), a validated 25-item self-report measure assessing symptoms associated with central sensitization. Scores range from 0 to 100, with scores of 40 or higher indicating the presence of a central sensitization syndrome.
Time frame: At six weeks
Assessed with a handheld digital algometer (Force One™, Wagner Instruments). Measurements will be taken at two sites: (1) the dorsal surface of the right third finger, midway between the distal and middle interphalangeal joints; and (2) a point 5 cm lateral to the right of the spinous process of the third lumbar vertebra (L3). A 1 cm² rubber tip will apply steadily increasing force until the participant first perceives pain; the force will be recorded in kilograms (kg). Three trials will be performed at each site, with 30 seconds of rest between trials, and the mean of the three readings for each site will be used for analysis. Lower pressure pain threshold (PPT) values (kg) indicate higher pain sensitivity. Higher PPT values indicate lower pain sensitivity.
Time frame: At six weeks
Measured with a handheld digital algometer (Force One™, Wagner Instruments) applied to the dorsal surface of the right third finger. Ten pressure pulses, each rising at 2 kg·s-¹ to the individual's mean pressure pain threshold, will be delivered at 1 Hz. Participants will rate pain intensity on a 0-10 verbal Numeric Rating Scale after the first and tenth pulses. The temporal summation (TS) score is calculated as NRS₁₀ - NRS₁ (range: -10 to +10), with positive values indicating temporal summation of pain, a marker of central sensitization.
Time frame: At six weeks
Assessed with a cuff-induced ischemic stimulus on the left upper arm. The cuff is inflated at 20 mm Hg·s-¹ until the first pain sensation, held for 30 seconds, then adjusted to maintain a pain intensity of 3/10 on the Numeric Rating Scale (NRS), and kept inflated. While the cuff remains on, a digital algometer delivers 10 pressure pulses to the dorsal surface of the right third finger: rising at 2 kg·s-¹ to the site-specific mean pressure pain threshold (PPT), held for 1 second, with 1 second of rest between pulses. Pain intensity is rated (0-10 NRS) after the first and tenth pulses. The conditioned pain modulation (CPM) effect is expressed as NRS₁₀ - NRS₁ (range -10 to +10). Lower or more negative values denote weaker endogenous pain inhibition.
Time frame: At six weeks
Assessed using the 30-Second Sit-to-Stand Test (STS-30), a functional test that evaluates lower limb strength and endurance by measuring an individual's ability to repeatedly rise from a chair without upper limb support over a 30-second period. The total number of repetitions performed during the 30-second period serves as an indicator of functional capacity, with higher scores reflecting better performance.
Time frame: At six weeks
Assessed using the Timed Up and Go (TUG) Test, a widely used clinical tool that evaluates gait speed, dynamic balance, and overall functional capacity. Participants are timed while rising from a chair, walking three meters, turning around, walking back, and sitting down. Shorter times indicate better functional performance.
Time frame: At six weeks
Measured using a handheld dynamometer, a widely applied tool for quantifying neuromuscular function in individuals with fibromyalgia. The portable device will be placed just above the ankle while the participant is seated with the knee flexed at 90°, in order to measure maximal voluntary isometric contraction (MVIC) of the quadriceps muscle.
Time frame: At six weeks
Measured with a Jamar hydraulic dynamometer, according to the protocol described by Hamilton et al. Participants will sit with feet flat on the floor, shoulder adducted and neutrally rotated, elbow flexed at 90°, and wrist and forearm in a neutral position. Three maximal trials will be performed with verbal encouragement, with at least 4-minute rest intervals between attempts. The average of the three trials will be used for analysis.
Time frame: At six weeks
Motivational regulation was assessed using the Behavioral Regulation in Exercise Questionnaire-3 (BREQ-3), a 24-item self-report instrument grounded in Self-Determination Theory. Each item is rated on a 5-point Likert scale (0 = "not true for me" to 4 = "very true for me"), producing six subscale scores-Amotivation, External Regulation, Introjected Regulation, Identified Regulation, Integrated Regulation, and Intrinsic Regulation-each ranging from 0 to 16. The total raw score ranges from 0 to 96, with higher values reflecting stronger endorsement of the statements. Depending on the pattern of subscale scores, elevated Intrinsic and Integrated Regulation scores indicate more autonomous motivation, whereas higher External Regulation and Amotivation scores denote more controlled or amotivated regulation.
Time frame: At six weeks
Dizziness will be monitored at every session using a 0-10 Numeric Rating Scale (NRS), where 0 indicates "no dizziness" and 10 indicates "worst imaginable dizziness." Dizziness will be captured as a continuous safety outcome, as it is expected to be the most frequent adverse effect of VR. Documenting its intensity will allow for timely adjustments to the intervention protocol. Higher scores will indicate greater levels of dizziness experienced during VR use.
Time frame: Immediately before and after each exercise session over the 6-week intervention period (two sessions per week).
Pain intensity will be recorded immediately before and after each exercise session using an 11-point Numeric Rating Scale (NRS-11) ranging from 0 ("no pain") to 10 ("worst imaginable pain"). Participants will be asked: "On a scale from 0 to 10, how intense is your pain right now?". Higher scores indicate greater pain intensity. The outcome will be calculated as the within-session change in pain (post-exercise minus pre-exercise score).
Time frame: At six weeks
Total weekly physical activity will be estimated using the International Physical Activity Questionnaire - Short Form (IPAQ-SF), a 7-item self-report tool validated in Spanish and recommended by the World Health Organization. Participants report the frequency and duration of walking, moderate, and vigorous physical activities over the previous seven days. Minutes of walking are weighted by 3.3 METs, moderate activity by 4.0 METs, and vigorous activity by 8.0 METs. These values are summed to yield a total MET-minutes-per-week score. The possible range is from 0 to no upper limit; higher values indicate greater energy expenditure.
Contact information is provided by the study sponsor or research team.
Cardenal Herrera University
Other
Effectiveness of an Immersive Virtual Reality-based Therapeutic Exercise Program With Altered Visual Feedback in Patients With Fibromyalgia: A Randomized Controlled Trial
Acronym: IVR-F
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07591766
Behavior, Fibromyalgia
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07200050
Behavior, Fibromyalgia
Kütahya, Turkey (Türkiye)
View Trial DetailsNCT06922747
Behavior, Connective Tissue Diseases
Tromsø, Troms, Norway
View Trial DetailsNCT01797263
Behavior, Fibromyalgia
Indianapolis, Indiana, United States
View Trial Details